SCHEMBL6659102

SCHEMBL6659102

CCC1OC(=O)N(CCc2ccc(NC(=O)c3cc[nH]n3)cc2)N=C1c1ccc(OC)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 13/20 0.41
PDE4A P27815 12/20 0.41
PDE4B Q07343 12/20 0.41
PDE4C Q08493 12/20 0.41
PDE3B Q13370 4/20 0.40
PDE3A Q14432 4/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
HSD17B10 Q99714 1/20 0.39
FLT1 P17948 1/20 0.38
KDR P35968 1/20 0.38
CFTR P13569 1/20 0.37
ABCB1 P08183 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.37
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656784 0.93 PDE4D (0.44) PDE4DPDE4APDE4BPDE4CPDE3B
SCHEMBL6654873 0.89 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CPDE3B
SCHEMBL6660162 0.89 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CPDE3B
SCHEMBL6692828 0.89 PDE4A (0.40) PDE4DPDE4APDE4BPDE4CPDE3B
SCHEMBL6655625 0.88 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CPDE3B
SCHEMBL6657358 0.88 SMN1; SMN2 (0.49) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6658460 0.87 PDE4D (0.39) PDE4DPDE4APDE4BPDE4CPDE3B
SCHEMBL6655740 0.87 PDE4A (0.40) PDE4DPDE4APDE4BPDE4CPDE3B
SCHEMBL6661778 0.87 PDE4A (0.42) PDE4DPDE4APDE4BPDE4CPDE3B
SCHEMBL6661400 0.87 PDE4D (0.38) PDE4DPDE4APDE4BPDE4CPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4D 12/4885PDE4A 1/4885PDE4B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.